Abstract
The bacteria-derived clustered regularly interspaced short palindromic repeat (CRISPR)–Cas systems are powerful tools for genome engineering. Recently, in addition to Cas protein engineering, the improvement of guide RNAs are also performed, contributing to broadening the research area of CRISPR–Cas9 systems. Here we develop a fusion guide RNA (fgRNA) that functions with both Cas9 and Cpf1 proteins to induce mutations in human cells. Furthermore, we demonstrate that fgRNAs can be used in multiplex genome editing and orthogonal genome manipulation with two types of Cas proteins. Our results show that fgRNAs can be used as a tool for performing multiple gene manipulations.
Similar content being viewed by others
Introduction
Clustered, regularly interspaced, short palindromic repeat (CRISPR)-Cas9 systems are widely used in the field of genome manipulation for gene editing and transcriptional and epigenetic perturbation1. Recently, others and we have shown that another Cas protein, Cpf1 (class 2, type V), can be successfully repurposed for genome editing of eukaryotic cells, animals, and plants2,3,4,5,6. Although both Cas9 and Cpf1 proteins are guide RNA (gRNA)-mediated endonucleases, the Cpf1 protein has several distinct properties compared with Cas9 protein (e.g., T-rich protospacer adjacent motif (PAM) sequences, PAM-distal region cutting, 5′-overhang sticky-end DSBs, and RNase activity), which provide significant increase in the potential application of the CRISPR-based genome manipulation toolbox.
In addition to the considerable effort expended on improving and developing Cas proteins7,8,9,10,11,12, gRNA engineering is being performed to refine the CRISPR–Cas9 and Cpf1 systems. Additional 5′-guanine or truncated gRNAs can reduce the mismatch tolerance and increase target specificity without sacrificing on-target activity13,14. Moreover, in addition to improving the specificity of CRISPR–Cas9 systems, gRNA engineering has broadened the set of potential applications of CRISPR–Cas9 systems. For example, aptamer-fused Cas9 gRNAs can recruit additional effector proteins, such as VP64, KRAB, and APOBEC, for genome manipulation15,16,17. Moreover, Cpf1 gRNAs have been engineered to simplify multiplex genome editing by exploiting the crRNA processing activity of the Cpf1 protein18. In this study, we develop a gRNA engineering method by creating a synthetic fusion gRNA (fgRNA) that can interact with both Cas9 and Cpf1 proteins. Using the fgRNAs, we demonstrate that fgRNAs can simultaneously induce endogenous mutations at both target sites of Cas9 and Cpf1, and that the mismatch tolerance of the fgRNAs is similar to that of conventional gRNAs. Furthermore, we show that the fgRNAs can work with dCas9 variants and Cpf1 to induce gene activation and disruption at endogenous target sites. On the basis of these results, fgRNAs have the potential to expand multiple gene manipulation using the orthogonality of various types of Cas proteins.
Results
fgRNAs mediated endogenous mutation
First, we carefully compared the gRNA composition of the Cas9 and Cpf1 systems. In CRISPR–Cas9 systems, the chimeric single gRNA (sgRNA) requires a tracrRNA fused at the 3′-end of the crRNA. In CRISPR–Cpf1 systems, crRNAs are composed of target-specific gRNA with a 5′-scaffold. In other words, the 3′-scaffold is necessary for CRISPR–Cas9 gRNAs and the 5′-scaffold is necessary for CRISPR–Cpf1 gRNAs. From these features, we constructed fgRNAs containing both the 5′-scaffold of Cpf1 and the 3′-scaffold of Cas9, with the expectation that the resultant fgRNAs would recruit both Cas9 and Cpf1 proteins to their target sites (Fig. 1a).
To investigate whether fgRNAs can guide both Cas9 and Cpf1 proteins to induce mutations in human cells, we chose VEGFA target sites that could be shared by LbCpf1 (Lachnospiraceae bacterium ND2006 Cpf1) and spCas9 (Streptococcus pyogenes Cas9). Using targeted deep sequencing, we found that fgRNAs could introduce endogenous indels with both Cas9 and Cpf1 proteins with comparable mutation frequencies to those of conventional gRNAs of spCas9 and LbCpf1 (95.5 and 86.9%, respectively, with spCas9 and 70.6 and 55.0%, respectively, with LbCpf1) (Fig. 1b). These findings were consistent with the results of other endogenous target sites, including FANCF and RUNX (Fig. 1c, d). We also fused fgRNAs with the 5′-scaffold of AsCpf1 (Acidaminococcus sp. BV3L6 Cpf1) instead of LbCpf1 and found that fgRNAs could also induce mutations at the endogenous RUNX locus in two different human cell lines, namely, HeLa and HEK293T (Supplementary Fig. 1a, b). In contrast to Cas9, Cpf1 possesses both RNase and DNase activities, which allow it to process its own pre-crRNA and subsequently use the processed RNA to recognize and cleave the target DNA. We also confirmed that fgRNAs recruit both Cpf1 and Cas9 proteins without any modification and might function with both Cpf1 and Cas9 proteins at each targeted locus (Supplementary Fig. 2). These results showed that fgRNAs can be used with both Cas9 and Cpf1 in targeted mutagenesis in human cells.
Potential off-target effects of fgRNAs
To assess the specificity of fgRNAs, we constructed a series of mismatched fgRNAs targeting human VEGFA sites and analyzed their mutagenesis activities using targeted deep sequencing (Fig. 2a). We found that fgRNAs had a similar level of mismatch tolerance to the conventional gRNAs of LbCpf1 and spCas9. We also investigated the specificity of human DNMT1-targeting fgRNA at several endogenous potential off-target sites defined in previous studies19,20. Notably, fgRNAs exhibited indel frequencies comparable to those of Cpf1 gRNAs at all potential off-target sites in HeLa cells (Fig. 2b).
Multiplex genome editing with fgRNAs
We next tested whether fgRNAs could be used in multiplex genome editing with Cas9 and Cpf1 proteins. For this purpose, the length of target-specific sequences between the 5′- and 3′-scaffolds were extended up to 40-bp for two different target sites. In preliminary experiments, we compared the mutagenesis activities of five fgRNAs containing sequences of different lengths between each scaffold and observed whether these fgRNAs could induce indels at human endogenous VEGFA sites. With both spCas9 and LbCpf1 proteins, no significant difference was observed in mutagenesis activities among all lengths of fgRNAs (22.5–28.8% with LbCpf1 and 68.6–75.8% with spCas9; Fig. 3). On the basis of these results, we hypothesized that fgRNAs could be simultaneously used to target two different genes with LbCpf1 and spCas9 (Fig. 4a). By co-transfecting fgRNA with LbCpf1 and spCas9, we successfully induced indels at endogenous VEGFA and FANCF loci (24.3 and 57.3%, respectively) and at VEGFA and TREX2 loci (29.9 and 64.1%, respectively) (Fig. 4b, c). We also successfully induced ssODN-mediated HDR in the VEGFA locus and gene disruption of the PRKDC locus in the same cells using fgRNAs (Supplementary Fig. 3).
Orthogonal genome manipulation with fgRNAs
Finally, we investigated whether fgRNAs could be used for orthogonal genome manipulation, especially for gene knockout and transcriptional activation of two different genes (Fig. 4a). For this purpose, we constructed fgRNAs containing target sequences of both endogenous MYOD and VEGFA genes. MYOD genes were successfully activated using a modified CRISPR–Cas9 system in a previous study21, and we designed fgRNAs that could simultaneously activate the MYOD gene and disrupt the VEGFA gene. By co-transfecting fgRNA-encoding plasmids with a MS2 loop, LbCpf1, dCas9-VP64, and MCP-p65-HSF1, we observed that MYOD mRNA expression levels increased >80-fold and found indel frequencies at the VEGFA locus to be 29.0% (Fig. 4d, e). We also observed orthogonal gene activation and disruption of endogenous ASCL1 and DNMT1 genes (Supplementary Fig. 4). These results revealed that fgRNAs could indeed be used in orthogonal gene disruption and activation with Cas9 variants and Cpf1 proteins. Taken together, these data highlight the utility of fgRNAs that recruit both Cas9 and Cpf1 proteins for efficient genome editing in human cells.
Discussion
CRISPR–Cas systems are widely used in various biological research fields for genome manipulation, and several efforts have been made to improve the nature of these systems. For example, Cas9 and Cpf1, which are representative proteins of the CRISPR system, are engineered for altering PAM sequences and improving target specificities8,9,14,22. Also, catalytically inactive Cas9 and Cpf1 are developed and widely used as programmable DNA-binding proteins for transcriptional and epigenetic perturbations1. As well as Cas proteins engineering, their gRNAs are also improved to increase indel frequencies, target specificities, and induce multiple genome editing13,14,18,23.
Cas9 and Cpf1 proteins have distinct characteristics, among which they have different gRNA structures. For this reason, it is necessary to make independent gRNAs even if they recognize the same target sequences. This is why there are no attempt to use the orthogonality of these two different types of Cas proteins, even though they might be complementary because of their distinct characteristics. In this study, we developed and validated fgRNAs—new gRNA constructs that can work with both Cas9 and Cpf1 proteins. In addition, by extending the target sequences of fgRNAs, we demonstrated that fgRNAs can be used for targeting two independent endogenous sites using Cas9 and Cpf1 proteins. We also demonstrated that fgRNAs could be used to induce gene disruption and activation simultaneously. With this concept, we believe that a variety of applications will be possible. For example, if fgRNAs are designed to direct dCas9 variants to key factors of DNA repair mechanisms and Cpf1 to wanted-target genes, it may be possible to alter the mutation frequencies or patterns of Cpf1. In addition to the fgRNA itself, fgRNAs combined with the above-mentioned engineered-Cas proteins and improved-gRNAs technologies would give rise to various possibilities applications. Taken together, fgRNAs have the potential to simplify multiple gene manipulation with various Cas proteins and expand the use of genome editing tools in biological research.
Methods
Construction of plasmid DNA
We used human codon-optimized spCas9 [p3s-Cas9HC (Addgene plasmids #43945)], LbCpf1 [pY016 (Addgene plasmids #69988)], and AsCpf1 [pY010 (Addgene plasmids #69982)]. Plasmid DNAs for orthogonal gene manipulation, lenti dCAS-VP64_Blast (Addgene plasmid #61425) and lenti MS2-p65-HSF1_Hygro (Addgene plasmid #61426) were gifts from Feng Zhang. pU6-As-crRNA (Addgene plasmid #78956) and pU6-Lb-crRNA (Addgene plasmid #78957) were used for cloning the gRNA of LbCpf1 and AsCpf1. To construct fgRNA-cloning vector, 5′-scaffold sequences of LbCpf1 (5′-AATTTCTACTAAGTGTAGAT-3′) and AsCpf1 (5′-TAATTTCTACTCTTGTAGAT-3′) were inserted behind the U6 promoter sequences of the Cas9 gRNA-cloning vector. The target sequences of each gRNA are listed in Supplementary Table 1.
Cell culture and transfection
HEK293T/17 (ATCC, CRL-11268) and HeLa (ATCC, CCL-2) cell lines were maintained in DMEM (WelGENE Inc.) supplemented with 10% FBS. 24 h before transfection, 2 × 105 HEK293T cells and 8 × 104 HeLa cells were seeded in 24-well plates (Corning). All transfection experiments were conducted using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s protocol. Cas protein expression plasmid DNA and gRNA-encoding plasmid DNA were transfected in each well of the 24-well plates in a 1:1 ratio. Each transfection was performed in duplicate. For ssODN-mediated HDR, 2 × 105 HeLa cells were nucleofected with spCas9 expression plasmid (200 ng), LbCpf1 expression plasmid (200 ng), VEGFA–PRKDC-targeting fgRNA (400 ng) and ssODN (100 pmol) according to the manufacturer’s protocols (Lonza). To perform single-clone analysis, cells were seeded in a 96-well plate at 0.5-cells per well density and single clones were analyzed 1 week after seeding. Cells were not tested for mycoplasma contamination.
NGS analysis for measuring mutation frequencies
Genomic DNA was extracted 72 h after transfection using the DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer’s protocol. The target region was amplified using Phusion High-Fidelity DNA Polymerase (New England Biolabs), and the PCR amplicons were subjected to paired-end sequencing using the Illumina MiSeq. The PCR primer sequences are listed in Supplementary Table 2. We used Cas-Analyzer (http://www.rgenome.net/cas-analyzer/) to analyze the mutation frequencies.
RNA expression level analysis
To analyze expression levels of MYOD and ASCL1 mRNA, total RNA was extracted using Riboclear (GeneAll) and cDNA was synthesized using AccuPower® CycleScript RT PreMix (Bioneer). Each cDNA sample was mixed with 2 × SYBR Green SuperMix (Bio-Rad) and subjected to real-time quantitative PCR (qPCR). MYOD and ACDL1 activation levels were calculated using the comparative CT method. Primer sequences used in qPCR are listed in Supplementary Table 2.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. All targeted deep sequencing data were deposited at NCBI Sequence Reads Archive database with accession number SRP116368.
Change history
16 January 2018
The originally published version of this Article contained an error in the spelling of the author Da-eun Kim, which was incorrectly given as Da-Eun Kim. Furthermore, in Figure 1a, the Cas9 protein was positioned incorrectly during typesetting. These errors have now been corrected in both the PDF and HTML versions of the Article.
References
Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014).
Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–771 (2015).
Kim, H. K. et al. In vivo high-throughput profiling of CRISPR-Cpf1 activity. Nat. Methods 14, 153–159 (2017).
Kim, Y. et al. Generation of knockout mice by Cpf1-mediated gene targeting. Nat. Biotechnol. 34, 808–810 (2016).
Kim, H. et al. CRISPR/Cpf1-mediated DNA-free plant genome editing. Nat. Commun. 8, 14406 (2017).
Hur, J. K. et al. Targeted mutagenesis in mice by electroporation of Cpf1 ribonucleoproteins. Nat. Biotechnol. 34, 807–808 (2016).
Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84–88 (2016).
Anders, C., Bargsten, K. & Jinek, M. Structural plasticity of PAM recognition by engineered variants of the RNA-guided endonuclease Cas9. Mol. Cell 61, 895–902 (2016).
Gao, L. et al. Engineered Cpf1 variants with altered PAM specificities. Nat. Biotechnol. 35, 789–792 (2017).
Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490–495 (2016).
Zetsche, B., Volz, S. E. & Zhang, F. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 33, 139–142 (2015).
Nihongaki, Y., Kawano, F., Nakajima, T. & Sato, M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. Nat. Biotechnol. 33, 755–760 (2015).
Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132–141 (2014).
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. & Joung, J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279–284 (2014).
Dahlman, J. E. et al. Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat. Biotechnol. 33, 1159–1161 (2015).
Zalatan, J. G. et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339–350 (2015).
Hess, G. T. et al. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat. Methods 13, 1036–1042 (2016).
Zetsche, B. et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array. Nat. Biotechnol. 35, 31–34 (2017).
Kim, D. et al. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat. Biotechnol. 34, 863–868 (2016).
Kleinstiver, B. P. et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. Nat. Biotechnol. 34, 869–874 (2016).
Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2015).
Kleinstiver, B. P. et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 523, 481–485 (2015).
Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015).
Acknowledgements
This work was supported by the National Research Foundation of Korea (2016R1D1A1A02937096, 2017M3A9B4062419, and 2016R1A6A3A04009014).
Author information
Authors and Affiliations
Contributions
J.K. and Y.K.: Designed the research. J.K., A.-H.J., D.K., J.W.Y., M.Y., and H.R.S.: Performed the experiments. J.K., J.-S.K. and Y.K.: Provided conceptual advice. J.K. and Y.K.: Wrote the paper. Y.K.: Supervised the research.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
A correction to this article is available online at https://doi.org/10.1038/s41467-017-02686-8.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kweon, J., Jang, AH., Kim, De. et al. Fusion guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1. Nat Commun 8, 1723 (2017). https://doi.org/10.1038/s41467-017-01650-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-017-01650-w
This article is cited by
-
Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity
BMC Biology (2022)
-
Multiplexed CRISPR technologies for gene editing and transcriptional regulation
Nature Communications (2020)
-
Genome editing in grass plants
aBIOTECH (2020)
-
Synthetic chimeric nucleases function for efficient genome editing
Nature Communications (2019)
-
High-throughput genetic screens using CRISPR–Cas9 system
Archives of Pharmacal Research (2018)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.